1st Global Advisors Inc. trimmed its stake in Shire PLC (NASDAQ:SHPG) by 4.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,642 shares of the biopharmaceutical company’s stock after selling 271 shares during the quarter. 1st Global Advisors Inc.’s holdings in Shire PLC were worth $932,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Verition Fund Management LLC grew its holdings in shares of Shire PLC by 18.9% in the 2nd quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock worth $490,000 after acquiring an additional 472 shares during the last quarter. Sterling Capital Management LLC acquired a new position in shares of Shire PLC in the 2nd quarter worth $299,000. Delphi Management Inc. MA grew its holdings in shares of Shire PLC by 10.5% in the 2nd quarter. Delphi Management Inc. MA now owns 13,350 shares of the biopharmaceutical company’s stock worth $2,206,000 after acquiring an additional 1,270 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Shire PLC by 6.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $1,073,000 after acquiring an additional 381 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in shares of Shire PLC by 3.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 1,839 shares of the biopharmaceutical company’s stock worth $280,000 after acquiring an additional 66 shares during the last quarter. Institutional investors and hedge funds own 19.28% of the company’s stock.

Shire PLC (NASDAQ SHPG) traded up 1.18% during mid-day trading on Friday, reaching $154.07. The company had a trading volume of 586,897 shares. The firm’s 50-day moving average price is $153.54 and its 200-day moving average price is $165.14. The stock has a market cap of $45.89 billion, a PE ratio of 68.94 and a beta of 1.63. Shire PLC has a 12 month low of $139.36 and a 12 month high of $194.60.

Shire PLC (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities research analysts forecast that Shire PLC will post $14.93 EPS for the current fiscal year.

The company also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.1527 per share. This represents a yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.

COPYRIGHT VIOLATION WARNING: “1st Global Advisors Inc. Sells 271 Shares of Shire PLC (SHPG)” was posted by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/10/14/1st-global-advisors-inc-sells-271-shares-of-shire-plc-shpg.html.

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada restated an “outperform” rating and issued a $213.00 target price on shares of Shire PLC in a report on Wednesday. Stifel Nicolaus restated a “buy” rating and issued a $245.00 target price on shares of Shire PLC in a report on Sunday, October 8th. Cantor Fitzgerald restated a “buy” rating and issued a $222.00 target price on shares of Shire PLC in a report on Thursday, September 14th. ValuEngine cut Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Evercore ISI assumed coverage on Shire PLC in a report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price on the stock. One analyst has rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the stock. Shire PLC currently has a consensus rating of “Buy” and an average price target of $220.91.

Shire PLC Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.